Benes, Cyril, and Stephen P. Soltoff. Modulation of PKC␦ tyrosine phosphorylation and activity in salivary and PC-12 cells by Src kinases. Am J Physiol Cell Physiol 280: C1498-C1510, 2001.-Protein kinase C (PKC) ␦ becomes tyrosine phosphorylated in rat parotid acinar cells exposed to muscarinic and substance P receptor agonists, which initiate fluid secretion in this salivary cell. Here we examine the signaling components of PKC␦ tyrosine phosphorylation and effects of phosphorylation on PKC␦ activity. Carbachol-and substance P-promoted increases in PKC␦ tyrosine phosphorylation were blocked by inhibiting phospholipase C (PLC) but not by blocking intracellular Ca 2ϩ concentration elevation, suggesting that diacylglycerol, rather than D-myo-inositol 1,4,5-trisphosphate production, positively modulated this phosphorylation. Stimuli-dependent increases in PKC␦ activity in parotid and PC-12 cells were blocked in vivo by inhibitors of Src tyrosine kinases. Dephosphorylation of tyrosine residues by PTP1B, a protein tyrosine phosphatase, reduced the enhanced PKC␦ activity. Lipid cofactors modified the tyrosine phosphorylation-dependent PKC␦ activation. Two PKC␦ regulatory sites (Thr-505 and Ser-662) were constitutively phosphorylated in unstimulated parotid cells, and these phosphorylations were not altered by stimuli that increased PKC␦ tyrosine phosphorylation. These results demonstrate that PKC␦ activity is positively modulated by tyrosine phosphorylation in parotid and PC-12 cells and suggest that PLC-dependent effects of secretagogues on salivary cells involve Src-related kinases. serine/threonine phosphorylation; parotid acinar; protein kinase C
THE INVOLVEMENT OF TYROSINE phosphorylation in heterotrimeric GTP-dependent protein (G protein)-coupled receptor-mediated events has been documented in many cellular systems, including freshly isolated cells and cultured cell lines. These events may involve the activation of nonreceptor tyrosine kinases such as Src and/or the transactivation of growth factor receptors (1, 6-8, 30, 43) . Previously, we observed that carbachol and substance P promoted rapid increases in the tyrosine phosphorylation of protein kinase C (PKC) ␦ in salivary gland epithelial cells (rat parotid acinar cells) (46) . In these cells, the muscarinic and substance P receptors are linked to phospholipase C (PLC)-␤ via a G q -type G protein. The activation of these G proteincoupled receptors (GPCRs) produces rapid increases in diacylglycerol (DAG) and D-myo-inositol 1,4,5-trisphosphate production, which promote the activation of PKC and increases in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ), resulting in the initiation of fluid secretion (saliva formation) by these cells. The rapid (within seconds) nature of tyrosine phosphorylation of PKC␦ after activation of these receptors suggests that PKC␦ may play a role in fluid secretion or other neurotransmitter-promoted events in these cells. Phorbol esters, which activate many PKCs, including PKC␦, also produce many regulatory effects on salivary cells, including the modulation of early response genes (55) , Ca 2ϩ -dependent K ϩ channels (33) , RNA synthesis (54) , cAMP response to ␤-adrenergic stimuli (53) , and exocytosis (56) . The present study had several goals, including the following: 1) to determine the factors involved in tyrosine phosphorylation of PKC␦ in freshly isolated salivary acinar cells; 2) to determine whether secretagogues alter PKC␦ enzyme activity and whether such alterations are dependent on tyrosine phosphorylation; and 3) to determine whether Src-related tyrosine kinases contribute to PKC␦ enzyme activity and tyrosine phosphorylation in salivary and other cells.
PKC␦ is a member of the PKC family of proteins, which is subdivided into three classes: Ca 2ϩ -dependent classic PKCs (cPKCs), consisting of ␣, ␤I, ␤II, and ␥; novel PKCs (nPKCs), consisting of ␦, ⑀, , and ; and atypical PKCs (aPKCs), consisting of and /. The cPKCs and nPKCs bind and are activated by DAG, for which phorbol esters can substitute. PKC␦ becomes tyrosine phosphorylated in cells exposed to various stimuli, including growth factors (10, 26, 27) and other receptor ligands (44, 46, 47, 50) , phorbol esters (10, 19, 46) , and H 2 O 2 (21, 49) , and in cells transformed with ras Ha or v-src (9, 58) . A number of groups have reported that PKC␦ can be tyrosine phosphorylated in vitro by c-Abl, Src, Lyn, and other members of the Src family of tyrosine kinases (2, 10, 14, 19, 47, 49, 50, 58) . However, there are conflicting reports concerning the contribution of tyrosine phosphorylation to the enzymatic ac-tivity of PKC␦ (13) . There was an increase in the tyrosine phosphorylation of PKC␦ in cells in which the oncogenes v-src (58) or ras Ha (9) were overexpressed, and this was associated with a decrease in PKC␦ enzymatic activity. In other cells, there was a positive association between tyrosine phosphorylation and PKC␦ enzyme activation in response to various stimuli (27, 28, 37) , and other studies failed to find any contribution of tyrosine phosphorylation in PKC␦ activity (26) .
PKC␦ has multiple tyrosine residues, and sites of tyrosine phosphorylation have been localized to the regulatory domain at the NH 2 -terminal side [Tyr-52 (50) and Tyr-187 (26) ], the catalytic domain at the COOH-terminal side of PKC␦ [Tyr-512 and Tyr-523 (21, 49) ], and at a site between the regulatory and catalytic domains [Tyr-311 (2) ]. Recent studies demonstrated that PKC␦ is phosphorylated on serine and threonine sites (23, 39, 40) similar to those on cPKC family members (4, 20) . In serum-starved cells, serum promoted the phosphorylation of a COOH-terminal hydrophobic site (Ser-662) on PKC␦ via a mammalian target of rapamycin (mTOR)-dependent pathway, and a site (Thr-505) in the activation loop of the kinase domain was phosphorylated by 3-phosphoinositide-dependent protein kinase-1 (PDK1), which itself is activated by the lipid kinase phosphatidylinositol (PtdIns) 3-kinase. These sites and another one (Ser-643) were critical for the functional activity of PKC␦. To put PKC␦ tyrosine phosphorylation in the context of Thr-505 and Ser-662 phosphorylation, we used phosphospecific antibodies to examine the phosphorylation status of PKC␦ on Thr-505 and Ser-662 in freshly isolated parotid cells exposed to stimuli that increase the tyrosine phosphorylation of PKC␦. We also examined the active involvement of mTOR and PtdIns 3-kinase in these phosphorylations in these cells.
On the basis of our previous findings, we examined various aspects concerning the mechanism of tyrosine phosphorylation of PKC␦ in freshly isolated rat parotid acinar cells. Little information is available concerning the role of tyrosine phosphorylation as a signaling mechanism by exposure of these salivary gland cells to GPCR ligands that promote fluid secretion. We investigated postreceptor events that could contribute to the tyrosine phosphorylation of PKC␦, including PLC activation, [Ca 2ϩ ] i elevation, and the involvement of protein tyrosine kinases and phosphatases. A major part of the present study was to determine whether tyrosine phosphorylation produced any alterations on the enzymatic activity of PKC␦ in parotid cells in response to secretory stimuli. To extend correlative observations that indicated that increases in PKC␦ tyrosine phosphorylation produced increases in PKC␦ activity, the reversibility of changes in enzymatic activity was examined by dephosphorylating PKC␦ in vitro using PTP1B, a protein tyrosine phosphatase. We also examined the in vitro and in vivo contributions of Src and Src-related kinases to PKC␦ activation and tyrosine phosphorylation. As a comparison for evaluating the contribution of tyrosine phosphorylation to PKC␦ activity in parotid acinar epithelial cells, we also examined this in PC-12 cells, a nonepithelial cell type.
MATERIALS AND METHODS
Chemicals. All chemicals were reagent grade or better. Carbamylcholine (carbachol), orthovanadate, and H2O2 were purchased from Sigma (St. Louis, MO). Pervanadate was formed by combining H 2O2 and vanadate in a 1:1 molar ratio and was made fresh on the day of the experiment. Substance P was obtained from Peninsula Laboratories (Belmont, CA). PMA (phorbol 12-myristate 13-acetate) was obtained from Life Technologies (Grand Island, NY). U-73122 was purchased from BioMol (Plymouth Meeting, PA). 4-Amino-5-(4-methylphenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine (PP1) was purchased from Calbiochem (La Jolla, CA) and BioMol. Anti-phosphotyrosine antibody was a generous gift of Dr. Thomas Roberts (Dana Farber, Boston, MA). Anti-PKC␦ polyclonal antibody (SC-213) and SRC2 antibody (SC-18; reactive toward p60
Src and other selected Src-related kinases, including p62
Yes and p59 Fyn ) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PKC␦ monoclonal antibody (MAb; P36520) was purchased from Transduction Laboratories (Lexington, KY). Phospho-PKC␦ (Thr-505) and phospho-PKC (pan) antibodies, which recognize the Thr-505 and Ser-662 sites, respectively, on PKC␦ were obtained from Cell Signaling (New England Biolabs). Anti-Src MAb (327) was a generous gift from Dr. Joan Brugge (Harvard Medical School, Boston, MA). Protein A-Sepharose beads and protein G-Sepharose beads were bought from Amersham Pharmacia. 1,2-Bis(2-aminophenoxy)ethane-N,-N,NЈ,NЈ-tetraacetic acid acetoxymethyl ester (BAPTA-AM) was purchased from Molecular Probes (Eugene, OR). Igepal was purchased from ICN Biomedicals (Costa Mesa, CA). Recombinant PTP1B (14-109) was purchased from Upstate Biotechnology (Lake Placid, NY) and was also a generous gift from Dr. Benjamin Neel (Beth Israel Deaconess Medical Center, Boston, MA). DAG and phosphatidylserine (PS) were purchased from Avanti Polar Lipids (Alabaster, AL). Dulbecco's modified Eagle's medium (DMEM) was purchased from Bio Whittaker (Walkersville, MD).
Cell preparation and solutions. Parotid acinar cells were prepared from male Sprague-Dawley rats (200-250 g; Charles River Laboratories, Kingston, NY, or Taconic, Germantown, NY) using previously established techniques (45) . Briefly, rat parotid glands were removed and treated with trypsin and collagenase to get a suspension of single cells and small groups of cells. Cells were suspended at 1-1.5 mg of protein/ml in a medium composed of the following: 116.4 mM NaCl, 5.4 mM KCl, 1 mM NaH2PO4, 25 mM sodium HEPES, 1.8 mM CaCl2, 0.8 mM MgCl2, 5 mM sodium butyrate, and 5.6 mM glucose, pH 7.4. Cells were maintained on ice before use. Aliquots (1.5 ml) of the cell suspension were equilibrated at 37°C for at least 10 min before exposure to stimuli. In experiments designed to examine the contribution of [Ca 2ϩ ]i to the tyrosine phosphorylation of PKC␦, cells were exposed to 25 M BAPTA-AM or vehicle (DMSO) for 30 min at 37°C before they were exposed to stimuli. In some experiments, 5 mM EGTA was also added to the BAPTA-loaded cells before the addition of stimuli.
PC-12 cells were cultured in DMEM containing heat-inactivated 10% calf serum, 5% heat-inactivated fetal calf serum, and 1% penicillin/streptomycin. Cells were grown in 100-mm dishes, used at ϳ75% confluence, and were serum starved in DMEM containing 0.1% serum overnight before exposure to stimuli.
Immunoprecipitations and Western blotting. Parotid cells were exposed to various agents or vehicle (water or DMSO) and were then collected by a brief spin in a microcentrifuge (Brinkmann 5414). The supernatant was removed, and cells were lysed in 1 ml of ice-cold lysis buffer [137 mM NaCl, 20 mM Tris base, pH 7.5, 1 mM EGTA, 1 mM EDTA, 10% (vol/vol) glycerol, and 1% vol/vol Nonidet P-40 (NP- 40) or Igepal] containing the following phosphatase and protease inhibitors: 1 mM vanadate, 1 mM ZnCl 2, 4.5 mM sodium pyrophosphate, 47.6 mM NaF, 9.26 mM ␤-glycerophosphate, 0.5 mM dithiothreitol (DTT), 2 g/ml leupeptin, 2 g/ml pepstatin, 2 g/ml aprotinin, and 2 g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride. The lysates were vortexed and then sedimented at 16,000 g for 15 min at 4°C. In experiments conducted using PC-12 cells, the cells were exposed to stimuli in DMEM containing 0.1% serum for the designated times, washed twice with ice-cold phosphate-buffered saline (PBS) solution (136.9 mM NaCl, 2.68 mM KCl, 1.47 mM KH 2PO4, and 15.65 mM NaH2PO4, pH 7.4), lysed in 1 ml of lysis buffer, vortexed, and then sedimented at 16,000 g for 15 min at 4°C. For parotid and PC-12 cell lysates, the cleared supernatants were added to fresh tubes, and proteins were immunoprecipitated using various antibodies in the following amounts: ϳ0.5 g/ml MAb PKC␦; 6 g/ml anti-PTyr; 2 g/ml MAb Src; and ϳ1 g/ml polyclonal PKC␦. Proteins were collected using protein A-Sepharose beads (4 mg/ml of lysate) except for the use of protein G-Sepharose (4 mg/ml) in experiments in which Src and PKC␦ were immunoprecipitated individually or simultaneously with antibodies to both proteins. The composition of the buffers and the washing protocols for the immunoprecipitations were performed as described previously, as were the Western blotting conditions (46) . For Western blotting, the nitrocellulose filters were exposed to the following dilutions of antibodies: anti-PKC␦ (polyclonal; SC-213), 0.2 g/ml; phospho-PKC␦ (Thr-505), 1:1,000 dilution; phospho-PKC (pan), 1:1,000 dilution; anti-P-Tyr, 1 g/ml; anti-Src (MAb 327), 1 g/ml; and SRC2, 0.2 g/ml.
In Western blotting experiments to determine whether PKC␦ and Src or Src-related kinases coimmunoprecipitated with each other, proteins that immunoprecipitated with polyclonal and monoclonal antibodies to PKC␦ were immunoblotted using polyclonal (SRC2) and MAb 327 Src antibodies. In addition, proteins that immunoprecipitated with anti-Src antibodies (MAb 327 and SRC2) were immunoblotted using polyclonal and monoclonal anti-PKC␦ antibodies. Proteins were visualized with a chemiluminescence system (NEN) and X-ray film (Kodak).
PKC␦ activity assay. Cells were exposed to various agents and then lysed in 1 ml of ice-cold lysis buffer. After the lysates were cleared by centrifugation for 15 min at 16,000 g, anti-PKC␦ MAb (ϳ0.5 g/ml) was added to the lysate for ϳ3 h at 4°C, and protein A-Sepharose (4 mg/ml) was added for 1 h to collect PKC␦. The immunoprecipitates were washed twice in PBS/NP-40 (1%) or PBS/Igepal (1%), once in 0.1 M Tris (pH 7.5)/LiCl (0.5 M), and twice in 25 mM Tris (pH 7.5)/0.5 mM EGTA/5 mM MgCl2/0.5 mM DTT. All wash solutions were used ice cold. The beads were resuspended in a final 100-l reaction buffer [5 mM MgCl2, 0.5 mM EGTA, 10 M PKC␦ synthetic substrate peptide (AKRKRKGSFFYGG), 1 mM DTT, and 25 mM Tris⅐HCl (pH 7.5)]. As noted, in some experiments the assays were conducted in the additional presence of 20 g/ml PS or the combination of 10 M DAG plus 20 g/ml PS in the assay buffer. The assays were initiated with the addition of ATP {50 M ATP and 10 Ci [␥- 32 P]ATP (10 Ci/l specific activity)}. The samples were incubated for 30 min at 30°C with intermittent mixing, and then duplicate 10-l aliquots of each sample were spotted onto p81 phosphocellulose paper. Background activity was measured using lysates to which protein A-Sepharose was added without antibody. The p81 papers were washed five times in 0.425% phosphoric acid, and the amount of 32 P was determined by liquid scintillation counting. The duplicate values from each immunoprecipitate were averaged and treated as one sample. Duplicate samples (2 separate immunoprecipitates) were usually collected for each of the various conditions in each experiment. The duplicate samples were averaged and treated as the results from one cell preparation (n ϭ 1). Statistics were performed on data from three or more separate preparations/experiments. These assay conditions were similar to those in a previous study in which the sequence of the substrate peptide, which is based on the pseudosubstrate region of PKC␦, was determined to be optimal for PKC␦ (35) . The basal and stimulated PKC␦ activities were completely blocked in vitro by the presence of various PKC inhibitors (1 M RO31-8220 or 1 M GF-109203X) in the assay mixture (not shown). Typical basal values ranged between 5,000 and 15,000 counts per minute, depending on the cell preparation.
Dephosphorylation of PKC␦ using PTP1B. In some experiments, immunoprecipitates were exposed to recombinant PTP1B (0.25 g, specific activity 67.8 nmol ⅐ min Ϫ1 ⅐ g Ϫ1 using p-nitrophenylphosphate). The immunoprecipitates were washed twice in PBS/Igepal (1%), once in 0.1 M Tris (pH 7.5)/LiCl (0.5 M), and twice in 25 mM Tris (pH 7.5)/0.5 mM EGTA/5 mM MgCl 2/5 mM DTT. Dephosphorylations or mock dephosphorylations (no added PTP1B) were performed in 100 l of this same buffer for 30 min at 30°C with intermittent mixing. After dephosphorylation, the immunoprecipitates were washed twice in PBS/1% NP-40 or Igepal, once in 0.1 M Tris (pH 7.5)/LiCl (0.5 M), and twice in 25 mM Tris (pH 7.5)/0.5 mM EGTA/5 mM MgCl2/0.5 mM DTT. PKC␦ activity assays were performed as described above.
Joint immunoprecipitation of Src and PKC␦. In experiments in which the effect of Src on PKC␦ activity was measured, cells were lysed in RIPA buffer (0.1% SDS, 1% NP-40 or Igepal, 0.5% deoxycholate, 158 mM NaCl, and 20 mM Tris, pH 8.0), and PKC␦ was immunoprecipitated using anti-PKC␦ MAb alone or a combination of anti-PKC␦ antibody and anti-Src (MAb 327) antibodies. In some experiments, Src was immunoprecipitated in the absence of PKC␦ using anti-Src antibody (MAb 327). The immunoprecipitates were collected with protein G-Sepharose beads and were washed three times in RIPA and twice in 20 mM HEPES (pH 7.4)/5 mM MgCl2/5 mM MnCl2. Some immunoprecipitates were subjected to in vitro phosphorylation reactions in the same buffer (Ϯ 100 M ATP) for 45 min at 30°C with intermittent mixing. The immunoprecipitates were washed twice in PBS/1% Igepal, once in 0.1 M Tris (pH 7.5)/LiCl (0.5 M), and twice in 25 mM Tris (pH 7.5)/0.5 mM EGTA/5 mM MgCl 2/0.5 mM DTT. PKC␦ activity assays were performed as described above. Some immunoprecipitates used for PKC␦ activity assays were subsequently used for Western blotting. For these samples, 2ϫ sample buffer was added to the immunoprecipitates after the PKC␦ assays were complete, and the samples were subjected to SDS-PAGE.
Data. The mean value Ϯ SE of n number of different experiments are as indicated. The percent inhibition of PKC␦ activity by various conditions was calculated as the difference between stimulated and basal activities in the inhibitory condition (PP1 in vivo or PTP1B in vitro) compared with the difference between stimulated and basal under control conditions. Statistics were performed using a paired t-test. Western blots are representative of at least three different experiments.
RESULTS
Tyrosine phosphorylation of PKC␦ is blocked by U-73122 in parotid cells exposed to carbachol or substance P but not PMA or pervanadate. In rat parotid acinar cells, the tyrosine phosphorylation of PKC␦ is increased in cells exposed to carbachol and substance P, which are agonists to PLC-linked GPCRs, as well as in cells exposed to PMA (46) . The GPCR-dependent changes in tyrosine phosphorylation occur very rapidly and are maximal within the first minute of exposure to receptor ligands (46) . To investigate whether PLC activation was involved in promoting the tyrosine phosphorylation of PKC␦, parotid cells were exposed to the PLC inhibitor (3, 12, 17, 57) U-73122 (10 M), which blocked the elevation of [Ca 2ϩ ] i in parotid acinar cells (not shown). The effects of carbachol and substance P were blocked in U-73122-treated cells (Fig. 1A) , suggesting that the receptor-mediated tyrosine phosphorylation of PKC␦ was initiated by the production of DAG or the elevation of [Ca 2ϩ ] i . The tyrosine phosphorylation of PKC␦ was also increased by pervanadate, an inhibitor of PTP1B (18), and other protein tyrosine phosphatases. Pervanadate (1 min) increased the tyrosine phosphorylation to a much greater level than carbachol (1 min) or PMA (5 min) (Fig. 1, B and C) . 1 The effects of PMA and pervanadate on the tyrosine phosphorylation of PKC␦ were not blocked by U-73122 (Fig. 1, B and C) , indicating that the effects of PMA and pervanadate are independent of PLC activity. The responses to pervanadate, which also increased the tyrosine phosphorylation of other proteins (not shown), suggest that the inhibition of a tyrosine phosphatase is sufficient to promote the tyrosine phosphorylation of PKC␦ in these cells. Unlike the effects of pervanadate, equivalent exposures (100 M, 1 min) of H 2 O 2 or vanadate were ineffective in producing large increases in the tyrosine phosphorylation of PKC␦ or other proteins (not shown). The effect of PMA on U-73122-treated cells suggests that the production of DAG is also sufficient to promote an increase in PKC␦ tyrosine phosphorylation. In addition, either the constitutive activity of a tyrosine kinase or a kinase that is activated by carbachol, substance P, PMA, and pervanadate is able to promote the tyrosine phosphorylation of PKC␦ in these epithelial cells. Additional experiments suggested that Src or a related protein kinase is the tyrosine kinase that phosphorylates PKC␦ in both parotid and PC-12 acinar cells.
Elevation of [Ca 2ϩ ] i does not contribute to PKC␦ tyrosine phosphorylation. Although we previously found that exposure of salivary gland epithelial cells to the Ca 2ϩ ionophore ionomycin did not promote the tyrosine phosphorylation of PKC␦ (46) , there was a possibility that elevations in [Ca 2ϩ ] i supported the stimulatory effects of carbachol and substance P on PKC␦ tyrosine phosphorylation. To examine this possibility, we loaded parotid acinar cells with the Ca 2ϩ chelator BAPTA, which buffers the carbachol-promoted rise in [Ca 2ϩ ] i in these cells (45) . BAPTA-loaded cells responded to carbachol in a similar manner as those cells that were not loaded with BAPTA (Fig. 2) . The carbachol-promoted increase in PKC␦ tyrosine phosphorylation was also observed in BAPTA-loaded cells that were exposed to EGTA to deplete extracellular Ca 2ϩ (not shown). These results indicate that a rapid rise in [Ca 2ϩ ] i was not required for the stimulatory effect of carbachol on PKC␦ tyrosine phosphorylation and demonstrate that another aspect of muscarinic receptor activation was responsible for the rapid increase in PKC␦ tyrosine phosphorylation. In conjunc- 1 The exposure of parotid cells to 100 M pervanadate for 1 min produced a larger increase in PKC␦ tyrosine phosphorylation than the effects of the exposure of these cells to PMA (100 nM) or carbachol (10 Ϫ4 M) for any time between 0 and 15 min. A: cells were exposed to vehicle (Ϫ), carbachol (Carb; 20 M, 1 min), or substance P (Sub P; 10 Ϫ7 M, 0.2 min). Proteins were immunoprecipitated (IP) with polyclonal anti-PKC␦ antibody and immunoblotted (IB) with anti-P-Tyr antibody (top). Left and right panels were from different experiments. One blot was stripped and reprobed with PKC␦ antibody (bottom) to show that there were similar levels of this protein in all samples. B: cells were exposed to vehicle (Ϫ), carbachol (20 M, 0.2 min), PMA (200 nM, 5 min), or pervanadate (Pervan; 100 M, 1 min). Proteins were immunoprecipitated with anti-P-Tyr antibody and immunoblotted with anti-PKC␦ antibody. C: cells were exposed to vehicle (Ϫ), pervanadate (100 M, 1 min), or carbachol (10 Ϫ4 M, 1 min). Proteins were immunoprecipitated with polyclonal anti-PKC␦ and immunoblotted with anti-P-Tyr antibody. Immunoblots were exposed to X-ray film for two different lengths of time to show that treatment of cells with U-73122 did not reduce their response to pervanadate. tion with the inhibitory effects of U-73122 on the substance P-and carbachol-promoted PKC␦ tyrosine phosphorylations ( Fig. 1) and the positive effect of PMA on PKC␦ tyrosine phosphorylation, these studies are consistent with DAG production playing the main role in the receptor-mediated increases in the tyrosine phosphorylation of PKC␦.
Tyrosine phosphorylation of PKC␦ increases the activity of PKC␦ in parotid acinar cells and PC-12 cells.
We performed in vitro substrate phosphorylation assays using PKC␦ immunoprecipitated from cells exposed to various stimuli. The exposure of parotid acinar cells to carbachol (10 Ϫ4 M, 1 min) increased the PKC␦ activity to 1.8 Ϯ 0.1 (n ϭ 4) times the basal level found in unstimulated cells. PMA (100 nM, 5 min) and pervanadate (100 M, 1 min) each increased PKC␦ activity by a much greater amount, to 4.1 Ϯ 1.0 (n ϭ 6) and 4.6 Ϯ 1.0 (n ϭ 4), respectively, times the basal level. These results suggested that the tyrosine phosphorylation of PKC␦ promoted an increase in PKC␦ activity in salivary acinar cells.
To determine whether these results were specific to salivary gland acinar cells, we performed similar experiments using PC-12 cells. PMA (100 nM, 5 min) increased PKC␦ activity to 2.5 Ϯ 0.1 (n ϭ 6) times the basal level in PC-12 cells. PMA (100 nM) added with pervanadate (100 M; both for 5 min) increased the PKC␦ activity to 3.5 Ϯ 0.5 (n ϭ 5) times the basal level. Under both conditions (Ϯ pervanadate), PMA produced an increase in tyrosine phosphorylation of PKC␦ (below).
The stimuli-dependent changes in PKC␦ activity were consistent with the conclusion that increases in the tyrosine phosphorylation of PKC␦ produce increases in PKC␦ activity in parotid and PC-12 cells. To test this hypothesis directly, we examined the effects of dephosphorylating the tyrosine-phosphorylated PKC␦ by using PTP1B, a protein tyrosine phosphatase, to see if the increases in PKC␦ activity were reversible. In these experiments, we collected anti-PKC␦ immunoprecipitates from cells exposed to agents that increased PKC␦ activity and tyrosine phosphorylation and exposed the immunoprecipitates to PTP1B to dephosphorylate PKC␦ in vitro before measuring PKC␦ activity (see MATERIALS AND METHODS). Immunoprecipitates that were not exposed to PTP1B were treated in an identical manner, except that PTP1B was not present in the dephosphorylation step. The effects of PTP1B on tyrosine phosphorylation were also analyzed. PTP1B dephosphorylated PKC␦ to near basal levels in immunoprecipitates from PMA-and pervanadate-treated parotid acinar cells (Fig. 3A) . PTP1B also dephosphorylated PKC␦ immunoprecipitated from carbacholtreated parotid acinar cells (not shown). Moreover, the dephosphorylations were accompanied by large reductions in the increased PKC␦ activity (Fig. 3B) . PTP1B treatment reduced the increases in response to carbachol, PMA, and pervanadate by 98.0 Ϯ 19.7% (n ϭ 4), 86.2 Ϯ 10.7% (n ϭ 6), and 79.6 Ϯ 21.8% (n ϭ 4), respectively. PTP1B did not significantly alter the Fig. 3 . PTP1B, a protein tyrosine phosphatase, reverses stimulusdependent increases in PKC␦ tyrosine phosphorylation and activity in parotid acinar cells. Parotid cells were exposed to carbachol (10 Ϫ4 M, 1 min), PMA (100 nM, 5 min), pervanadate (PV; 100 M, 1 min), or left untreated (B, basal). PKC␦ was immunoprecipitated with an anti-PKC␦ MAb. Immunoprecipitates were exposed to a dephosphorylation buffer with PTP1B or without (mock) PTP1B for 30 min, and the immunoprecipitates were washed and subjected to a substrate phosphorylation assay to quantify activity (B). After the assay, immunoprecipitates were subjected to SDS-PAGE on a 7% separating gel, transferred to nitrocellulose, and immunoblotted. A: immunoprecipitated PKC␦ was immunoblotted with an anti-P-Tyr antibody (top). Blots were stripped and reprobed with polyclonal anti-PKC␦ antibody (bottom). The open arrowhead indicates the tyrosine-phosphorylated form of PKC␦, and the closed arrowhead indicates the nontyrosine-phosphorylated form. B: alterations in PKC␦ activity in anti-PKC␦ immunoprecipitates exposed (PTP1B) or not exposed (mock) to PTP1B. All activity values are normalized to the activity found under basal conditions without PTP1B treatment. For carbachol, PMA, and pervanadate, n ϭ 4, 6, and 4, respectively.
## P Ͻ 0.001 and # P Ͻ 0.005 vs. basal (mock). **P Ͻ 0.001 and *P Ͻ 0.005 vs. stimulus ϩ mock treatment. basal PKC␦ activity in untreated parotid acinar cells (Fig. 3B) , consistent with the low or absent tyrosine phosphorylation of PKC␦ in untreated cells. These results demonstrate conclusively that increases in tyrosine phosphorylation produce increases in PKC␦ activity that can be reversed when tyrosine residues are dephosphorylated.
We also examined the effects of PTP1B-mediated dephosphorylation on PKC␦ in PC-12 cells to determine whether the effects of tyrosine phosphorylation on PKC␦ activity were reversible. Exposure of PC-12 cells to PMA or PMA plus pervanadate produced large increases in PKC␦ tyrosine phosphorylation, and exposure of the immunoprecipitates to PTP1B dephosphorylated PKC␦ (Fig. 4A) . PTP1B also reduced the increase in PKC␦ activity. The increases in PKC␦ activity in cells treated with PMA or PMA plus pervanadate were reduced by 66.9 Ϯ 0.2% (n ϭ 6) and 60.4 Ϯ 11.5%
(n ϭ 5), respectively (Fig. 4B) .
2 PTP1B did not significantly affect the basal PKC␦ activity in PC-12 cells (Fig. 4B) . These results are similar to those obtained using salivary gland acinar cells and conclusively demonstrate that tyrosine phosphorylation of PKC␦ can increase the activity of PKC␦ in a reversible manner in multiple types of cells.
Increases in PKC␦ tyrosine phosphorylation retard the migration of PKC␦ through SDS-polyacrylamide gels, as observed previously in parotid acinar cells (46) . This produced a doublet in PKC␦ when anti-PKC␦ immunoprecipitates were immunoblotted using anti-PKC␦ antibody, especially when a significant fraction of PKC␦ was phosphorylated on tyrosine (Fig. 4A) . The tyrosine-phosphorylated PKC␦ comigrated with the top band. The in vitro dephosphorylation of PKC␦ by PTP1B decreased the appearance of the top band in the anti-PKC␦ immunoblots (Fig. 4A) and decreased the amount of tyrosine-phosphorylated PKC␦ when the anti-PKC␦ immunoprecipitates were immunoblotted using anti-P-Tyr antibody (Fig. 4A) . These results suggest that the top band of PKC␦ consists nearly exclusively of the tyrosine-phosphorylated protein.
Stimuli-dependent increases in PKC␦ activity did not occur in presence of lipid cofactors. The alterations in PKC␦ activity in parotid and PC-12 cells presented above were measured in the absence of lipid cofactors and reflect an increase in PKC␦ activity that is intrinsic to the immunoprecipitated protein and not due to increases in protein levels. When PS was present in the assay mixture (see MATERIALS AND METHODS), the PKC␦ activity in immunoprecipitates from PMA (100 nM, 5 min)-stimulated PC-12 cells was significantly greater than the activity in unstimulated cells, but the degree of stimulation was less than that measured in assays conducted in the absence of added lipids (Fig. 5) . Note, however, that the basal activity in the presence of PS in vitro was approximately three times that measured in the absence of PS (see Fig. 5 legend) . When DAG and PS were both present in the assay mixture, the basal PKC␦ activity in anti-PKC␦ immunoprecipitates from unstimulated PC-12 was increased to 28.9 Ϯ 4.2 (n ϭ 3) times the activity measured in the absence of lipid cofactors. However, in the presence of DAG plus PS, the PKC␦ activity found in immunoprecipitates from stimulated PC-12 cells was not enhanced compared with the activity in immunoprecipitates from unstimulated cells. For example, under these conditions (PSϩDAG) the activity in PMA (100 nM, 5 min)-treated cells was 0.9 (n ϭ 2) times that in untreated cells (Fig. 5) , and the activity in PMA (100 nM, 5min) plus pervanadate (100 M, 5 min)-treated cells was 1.0 Ϯ 0.1 (n ϭ 4) times the activity in untreated cells. Thus the contribution of tyrosine phosphorylation to PKC␦ activity was not manifested when DAG and PS Fig. 4 . PTP1B reverses increases in PKC␦ tyrosine phosphorylation and activity in PC-12 cells exposed to PMA and pervanadate. PC-12 cells were exposed to vehicle or PMA (100 nM) Ϯ pervanadate (100 M) for 5 min. PKC␦ was immunoprecipitated with anti-PKC␦ MAb. Immunoprecipitates were exposed to a dephosphorylation buffer with or without PTP1B for 30 min, and they were washed and subjected to a substrate phosphorylation assay to quantify activity (B). After assay, immunoprecipitates were subjected to SDS-PAGE on a 7% separating gel, transferred to nitrocellulose, and immunoblotted. A: immunoprecipitated PKC␦ was immunoblotted with an anti-P-Tyr antibody (top). Blots were stripped and reprobed with polyclonal anti-PKC␦ antibody (bottom). The open arrowhead indicates the tyrosine-phosphorylated form of PKC␦, and the closed arrowhead indicates the nontyrosine-phosphorylated form. B: alterations in PKC␦ activity in anti-PKC␦ immunoprecipitates exposed (PTP1B) or not exposed (mock) to PTP1B. All activity values are normalized to the activity found under basal conditions without PTP1B treatment. For PMA and PMA ϩ pervanadate, n ϭ 6 and 5, respectively.
## P Ͻ 0.001 vs. basal (mock). **P Ͻ 0.001 vs. stimulus ϩ mock treatment.
were both present in the assay, as was also reported by others (21, 36) . Similar findings were made using parotid acinar cells. When DAG plus PS were present in the assay mixture, the basal PKC␦ activity in anti-PKC␦ immunoprecipitates from unstimulated parotid cells was increased to 24.4 Ϯ 4.3 (n ϭ 3) times the activity in the absence of lipids. Also, in assays conducted with DAG plus PS in the assay mixture, the PKC␦ activity found in immunoprecipitates from unstimulated cells was the same as the activity in cells treated with carbachol, PMA, or pervanadate (not shown). These results bear on the biological significance of the activation of PKC␦ (see DISCUSSION) .
Src phosphorylates PKC␦ and increases its enzymatic activity. Previously, we found that a kinase inhibitor, staurosporine, and genistein, a nonselective tyrosine kinase inhibitor, blocked the tyrosine phosphorylation of PKC␦ (5) . Because several investigators have suggested a role for Src, Src-related kinases, and other tyrosine kinases in the tyrosine phosphorylation of PKC␦, we conducted several experiments to determine whether Src-related proteins are involved in the activation of PKC␦ by receptor-mediated and nonreceptormediated agents in parotid cells and PC-12 cells. In one series of in vivo experiments, parotid acinar cells were treated with PP1, an inhibitor of Src and Src family members (16) , and then the cells were exposed to agents that promoted increases in PKC␦ tyrosine phosphorylation and activity. Treatment of parotid cells with PP1 blocked carbachol-and pervanadate-promoted increases in tyrosine phosphorylation (Fig. 6A) . PP1 also blocked the effects of PMA on PKC␦ tyrosine phosphorylation (not shown). PP1 treatment of parotid cells also blocked the increases in PKC␦ activity pro- To compare the relative effects of PMA under these 3 conditions, the basal activities (Ϯ PS/DAG) were each normalized to 100. Basal PKC␦ activity assayed in the presence of PS was 2.9 Ϯ 1.2 (n ϭ 4) times that measured in the absence of lipids, and basal activity in the presence of DAGϩPS was 28.9 Ϯ 4.2 (n ϭ 3) times the activity measured in the absence of lipids. **P Ͻ 0.005 vs. basal, PS absent (n ϭ 4). *P Ͻ 0.05 vs. basal, PS present (n ϭ 4).
moted by carbachol, PMA, and pervanadate by 78.2% (n ϭ 2), 83.1 Ϯ 6.6% (n ϭ 3), and 67.3 Ϯ 21.3% (n ϭ 3), respectively (Fig. 6B) . PP1 treatment did not significantly reduce the basal activity in parotid cells (Fig.  6B ), consistent with a role for Src in the increase of PKC␦ activity but not in basal activity. PP1 blocked the tyrosine phosphorylation of PKC␦ in PMA (Ϯ pervanadate)-treated PC-12 cells (Fig. 6C) , and it also blocked the PMA-promoted increase in PKC␦ activity by 74.8% (n ϭ 2). These results suggest that the in vivo activity of Src or an Src-like protein is responsible for the increases in PKC␦ tyrosine phosphorylation and the resulting increases in PKC␦ activity in both parotid acinar cells and PC-12 cells. These results also suggest that a Src-related kinase is involved in tyrosine phosphorylation that is promoted by diverse agents: PLClinked receptor agonists, phorbol ester, and a phosphatase inhibitor.
In some systems, Src-related proteins may coimmunoprecipitate with PKC␦. Although we immunoblotted anti-PKC␦ immunoprecipitates for Src and several Srcrelated proteins and vice versa, we were unable to observe any association between these proteins in either PC-12 cells or parotid acinar cells in response to various stimuli or under basal conditions ( Fig. 7A and unpublished observations; see MATERIALS AND METHODS). However, the in vivo experiments shown in Fig. 6 suggested that a Src-related tyrosine kinase was involved in the activation of PKC␦. Therefore, we examined whether Src was able to increase the tyrosine phosphorylation and activity of PKC␦ in vitro. In these experiments, we immunoprecipitated PKC␦, Src, or PKC␦ plus Src from unstimulated parotid acinar cell lysates using antibodies to both PKC␦ and Src. Some of the immunoprecipitated proteins were subjected to in vitro conditions (incubation with ATP and divalent cations) that promote substrate phosphorylation by tyrosine kinases, and then the activity of PKC␦ was assayed. There was a substantial tyrosine phosphorylation of PKC␦ (Fig. 7A) only when immunoprecipitated Src was also present. There was not a significant degree of tyrosine phosphorylation of PKC␦ when it was immunoprecipitated by itself (no Src antibody), even if the immunoprecipitate was subjected to conditions that promote tyrosine phosphorylation (Fig. 7A) . The tyrosine phosphorylation of the PKC␦ that was immunoprecipitated jointly with Src was blocked if PP1 was present.
In these in vitro experiments, there was a significant increase in PKC␦ activity under conditions (joint immunoprecipitation of Src and PKC␦) that promoted the increase in tyrosine phosphorylation of PKC␦ (Fig. 7B ). This increase in activity was blocked by PP1 in vitro. No increases in PKC␦ activity were observed if immunoprecipitated Src was not present, even if PKC␦ was subjected to in vitro phosphorylation conditions before the activity assay. Immunoprecipitates of Src without PKC␦ did not display measurable PKC activity (not shown). Thus when these changes in activity are compared with the alterations in tyrosine phosphorylation, they indicate that the tyrosine phosphorylation of PKC␦ has a positive effect on PKC␦ activity in a Srcdependent manner. The in vitro PP1-sensitive Srcpromoted increases in PKC␦ activity and tyrosine phosphorylation (Fig. 7) are consistent with the inhibitory effects of in vivo PP1 on PKC␦ activity (Fig. 6 ) being due to the inhibition of Src or a Src-like protein.
The results of these in vitro and in vivo experiments indicate that Src or a Src-related protein increases the tyrosine phosphorylation of PKC␦ in cells in which Fig. 7 . PKC␦ tyrosine phosphorylation and activity is increased by Src in parotid acinar cells. PKC␦ was immunoprecipitated from unstimulated parotid acinar cell lysates with either an anti-PKC␦ MAb alone or simultaneously with an anti-Src MAb. Some immunoprecipitates were subjected to conditions (ATP) to promote tyrosine phosphorylation (see MATERIALS AND METHODS). Immunoprecipitates were washed and then subjected to a substrate phosphorylation assay to quantify PKC␦ activity. When present, PP1 was added during both the in vitro tyrosine phosphorylation and the activity assay. A: immunoprecipitated proteins were subjected to SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-P-Tyr antibody (top). Blots were stripped and reprobed with anti-PKC␦ antibody (middle) and anti-Src (MAb 327) antibody (bottom). The open arrowhead indicates the tyrosine-phosphorylated form of PKC␦, and the closed arrowhead indicates the nontyrosine-phosphorylated form. B: PKC␦ activity in anti-PKC␦ immunoprecipitates with and without immunoprecipitated Src (see MATERIALS AND METH-ODS). All activity values are normalized to the activity found in anti-PKC␦ immunoprecipitates that were not subjected to tyrosine phosphorylation reaction. *P Ͻ 0.01 vs. basal (PKC, no ATP); ## P Ͻ 0.005 vs. PKC ϩ ATP; ϩ P Ͻ 0.05 vs. no PP1. For each condition, n ϭ 3 experiments.
GPCRs are activated, protein tyrosine phosphatases are inhibited, or PKC is activated by phorbol ester. These increases in tyrosine phosphorylation increase the enzymatic activity of PKC␦.
Tyrosine phosphorylation of PKC␦ does not alter constitutive serine and threonine phosphorylations. PKC␦ is also phosphorylated on particular serine and threonine residues that can affect PKC␦ activity. To put PKC␦ tyrosine phosphorylation in the context of Thr-505 and Ser-662 phosphorylation, we examined the phosphorylation of PKC␦ on Thr-505 and Ser-662 in rat parotid acinar cells exposed to carbachol and PMA. Because PtdIns 3-kinase and mTOR activities are upstream of the phosphorylation of these sites (39, 40) , we treated cells with the PtdIns 3-kinase inhibitor LY-294002 and the mTOR inhibitor rapamycin. In parotid cells, Thr-505 and Ser-662 sites were constitutively phosphorylated under basal conditions. These phosphorylations were not reduced by exposure of cells to LY-294002 (100 M) or rapamycin (20 nM; Fig. 8 ) for times up to 30 min. The PtdIns 3-kinase inhibitor wortmannin (100 nM) gave similar results to LY-294002 (not shown). No alterations in the constitutive Thr-505 or Ser-662 phosphorylations were observed in cells exposed to 100 M carbachol for 1-10 min (not shown) or PMA for 5 min (Fig. 8 ) or 10 min (not shown) in control cells or in cells exposed to PtdIns 3-kinase and mTOR inhibitors. The increases in PKC␦ tyrosine phosphorylation promoted by PMA (Fig. 8) and carbachol (not shown) were not affected by the presence of these inhibitors. In stimulitreated cells, the more slowly migrating top band of PKC␦ was phosphorylated on Thr-505 and Ser-662 in addition to tyrosine residues, but the bottom band was only phosphorylated on Thr-505 and Ser-662. These results indicate that tyrosine phosphorylation of PKC␦ in freshly isolated parotid cells occurs in the absence of any change in Thr-505 and Ser-662 phosphorylation.
DISCUSSION
A major reason for undertaking these studies was to examine the contribution of tyrosine phosphorylation to PKC␦ enzyme activity in rat parotid acinar cells, which respond to secretory stimuli with an increase in PKC␦ tyrosine phosphorylation. We also examined PC-12 cells as a second cell model. From our results, we conclude the following: 1) the activation of PLC and the production of DAG account for muscarinic and substance P-mediated increases in PKC␦ tyrosine phosphorylation in parotid acinar cells; 2) increases in the tyrosine phosphorylation of PKC␦ by receptor-mediated and nonreceptor-mediated agents have a positive effect on PKC␦ enzyme activity in both parotid and PC-12 cells; 3) the activation of PKC␦ is reversible upon the dephosphorylation of the tyrosine residues; 4) Src or Src-related proteins phosphorylate PKC␦ on tyrosine in vivo and in vitro, and this increases its activity; and 5) the stimuli-dependent tyrosine phosphorylation of PKC␦ in freshly isolated salivary cells occurs subsequent to its phosphorylation on Thr-505 and Ser-662.
PKC␦ was activated by receptor-mediated stimuli (carbachol), by PMA, which bypasses PLC (Fig. 1) , and by pervanadate. Pervanadate does not appear to act by stimulating PLC (Fig. 1) ; presumably, it promotes the tyrosine phosphorylation of PKC␦ by inhibiting tyrosine phosphatase activity. Increases in carbacholmediated PKC␦ tyrosine phosphorylation in parotid cells were blocked by inhibiting PLC (Fig. 1 ) but were not blocked by preventing the elevation of [Ca 2ϩ ] i (Fig.  2) , suggesting that DAG production initiated the activation of PKC␦ in parotid acinar cells in a Ca 2ϩ -independent manner. Previously, we reported that the tyrosine kinase inhibitor genistein blocked increases in the tyrosine phosphorylation of PKC␦ (5) . The data presented in this paper suggests that Src or a Srcrelated kinase is the tyrosine kinase that phosphorylates PKC␦ in these cells. In addition, these studies suggest that both protein tyrosine kinases and phosphatases affect the tyrosine phosphorylation and activity of PKC␦.
A model for PKC␦ tyrosine phosphorylation is as follows: the production of DAG in response to PLClinked receptor activation, or, bypassing this step, the exposure of cells to PMA promotes the recruitment of PKC␦ to the plasma membrane, where PKC␦ is a substrate for Src or other Src-like proteins and is phosphorylated on tyrosine residues that contribute to increases in PKC␦ activity. Previously, we demonstrated that PMA promoted the translocation of PKC␦ from the cytosol to a membrane compartment of salivary gland acinar cells, and the tyrosine phosphorylated form of PKC␦ was exclusively found in the membrane compartment (46) . Other investigators have made similar observations concerning the localization of tyrosine-phosphorylated PKC␦ (13, 19, 24, 58) , al- though an alternative finding of PMA-promoted tyrosine-phosphorylated PKC␦ in the cytosol has also been reported (42) .
Presumably, membrane-localized PKC␦ is a substrate for Src or a Src-related protein that is constitutively active and able to phosphorylate PKC␦ in cells exposed to GPCRs, PMA, and pervanadate. Other proteins known to be Src substrates are constitutively phosphorylated on tyrosine residues in unstimulated parotid cells (unpublished observations). Src can also be directly activated by ␣-subunits of G proteins (31) , but this cannot account for the stimulation promoted by PMA or pervanadate. Under the conditions of our experiments, we did not find a physical association between Src or Src-related proteins and PKC␦. If this association occurred, it did not survive our immunoprecipitation protocol or was too subtle to detect by immunoblot techniques. In other cellular systems, PKC␦ was coimmunoprecipitated with Src and members of the Src family (42, 47, 58) . PKC␦ and c-Abl associate in response to oxidative stress (H 2 O 2 ), and each of these two proteins affects the activity of each other (49) .
Studies of PKC␦ using serum-starved cells indicate that serum can promote increases in the phosphorylation of Thr-505 and Ser-662. Under these conditions, these sites were crucial for PKC␦ activity, and the phosphorylation of these sites were dependent on pathways involving PtdIns 3-kinase and mTOR (39, 40) . In our experiments using freshly isolated parotid cells, these sites were constitutively phosphorylated and were not changed by exposure to PtdIns 3-kinase and mTOR inhibitors (Fig. 8) . Presumably, cellular serine/ threonine phosphatases were ineffective in dephosphorylating Thr-505 and Ser-662 during the relatively brief (30-min) exposure of cells to these inhibitors. This may not be surprising, because cultured cells must be serum starved (23) and maintained in suspension (38, 40) to reduce the phosphorylation of these sites before stimulation by serum. Phosphorylations of the basal serine and threonine phosphorylation sites were also not affected by secretory stimuli (carbachol) and other PKC-activating agents (PMA). These PKC␦ sites had already been phosphorylated in the salivary cells, and tyrosine phosphorylation occurred subsequent to threonine and serine phosphorylation. The basal phosphorylation status of the cells did not allow us examine alterations in tyrosine phosphorylation under conditions in which the enzyme was not phosphorylated on Thr-505 and Ser-662, and, therefore, we cannot conclude that tyrosine phosphorylation and its effects on PKC␦ activity absolutely require the prior phosphorylation of these threonine and serine sites. It also should be noted that a contrasting argument has been made that Glu-500, an acidic residue in the activation loop, rather than phosphorylated Thr-505, is required for the catalytic activity of PKC␦ (48) .
There have been contrasting studies concerning the contribution of tyrosine phosphorylation to the activity of PKC␦. Because there are multiple tyrosine residues on PKC␦, phosphorylation of the different residues could have quite different effects on the absolute activity of PKC␦ and/or the biological activity of PKC␦. Evidence of the latter was recently suggested (22) . Thus our findings may be restricted to activation of PKC␦ by PLC-linked receptor activation, phorbol ester, and pervanadate treatment of these cells. In CHO-K1 cells, PKC␦ activity was increased by activation of a G protein-coupled ATP-binding receptor by PMA and by H 2 O 2 (37) . The degree of maximal activation by these stimuli was H 2 O 2 Ն PMA Ͼ ATP, and the relative amount of tyrosine phosphorylation also followed this relative order, although no significant degree of phosphorylation was detected for ATP. These results are similar to the relative order of stimuli acting on salivary gland cells: pervanadate Ն PMA Ͼ carbachol.
The exposure of parotid cells to 100 M pervanadate produced a much larger increase in PKC␦ tyrosine phosphorylation than did exposure of the cells to 100 nM PMA (Figs. 1C and 4A ), yet both agents produced about the same degree of increase in PKC␦ activity (Fig. 4B ). This suggests that multiple tyrosine residues on PKC␦ can be phosphorylated but that not all of the phosphorylated tyrosine residues contribute to increases in PKC␦ activity. This may be true for increases in tyrosine phosphorylation promoted by PMA and GPCR ligands as well as by pervanadate. On the basis of mutational studies and an analysis of tryptic digests of PKC␦, Blake et al. (2) concluded that Src phosphorylated Tyr-311 but that additional tyrosine sites were subsequently phosphorylated. Thus the relative degree of stimuli-dependent increases in PKC␦ activity is not necessarily quantitative with the relative increases in tyrosine phosphorylation, especially when different stimuli are compared.
The tyrosine phosphorylation of PKC␦ produced at most an increase in activity to levels four to five times the basal level (Fig. 6B) . However, the tyrosine-phosphorylated form of PKC␦, which migrated more slowly through an SDS-PAGE gel (Figs. 3A, 4 , A and C, and 6A), constituted at most one-half of the total PKC␦ protein in cells exposed to PMA and pervanadate in both cell types. Thus the tyrosine-dependent increases in PKC␦ activity would be at least twice the values as those reported here if all of the PKC␦ in the samples were composed of the tyrosine-phosphorylated form. In parotid cells exposed to carbachol, the tyrosine-phosphorylated form of PKC␦ made up a much lower fraction of the total PKC␦ (46) , and this would appear to account for the relatively smaller increase in PKC␦ activity promoted by carbachol compared with PMA or pervanadate. Stimuli-dependent increases in activity due to tyrosine phosphorylation were not observed in the presence of DAG and PS, which increased the assayed activity to a much greater level than that produced by tyrosine phosphorylation, but stimuli-dependent increases in activity were observed (albeit to a lesser relative extent) in the presence of PS alone (Fig.  3) . Presumably, tyrosine phosphorylation and lipid production both affect PKC␦ activity in vivo, and the membrane lipid composition in vivo may not be that which is idealized under in vitro conditions. In vivo, PKC␦ may localize at a site that has a lipid composition much different from that which permits the maximal activation of the enzyme in vitro. PKC␦ also may have a biological role in a nonmembrane compartment or in a membrane compartment distinct from the plasma membrane. In fact, PKC␦ was found to sequentially localize to nuclear and Golgi membranes after it translocated to the plasma membrane in response to PMA and other phorbol ester derivatives (51) . In some cells, phorbol ester initiated the translocation of PKC␦ to the mitochondria where it was involved in promoting apoptosis (32) . The translocation of PKC␦ to a new location will increase PKC␦ activity at that location. In addition to affecting PKC␦ activity, tyrosine phosphorylation can alter the substrate specificity of PKC␦ (15) as well as the lipid dependence (19) . Thus changes in location and changes in various enzymatic parameters may affect the biological activity of PKC␦.
PKC␦ is an important signaling protein that produces various effects on cells (for review, see Ref. 13) , including alterations of cell growth (29, 52) . In PC-12 cells, PKC␦ modulated the upregulation of L-type Ca 2ϩ channels in ethanol-treated cells (11) and also appeared to play a role in nerve growth factor-mediated neurite outgrowth (36) . PKC␦ was involved in receptor-mediated activation of the Na ϩ -K ϩ -Cl Ϫ cotransport system in human tracheal epithelial cells (25) and affected the permeability of tight junctions in LLC-PK 1 epithelial cells (34) . We did not directly address the physiological role of PKC␦ in rat parotid acinar epithelial cells, but the activation of parotid muscarinic receptors, which increases PKC␦ activity, stimulates both fluid secretion as well as a Ca 2ϩ -sensitive component of exocytosis of protein secretory granules (56) . PKC␦ may play a role in these events. PKC␦ plays a critical role in etoposide-induced apoptosis in a cultured rat parotid acinar cell line (41) . However, this was mediated by the caspase-dependent cleavage of PKC␦ to its constitutively activated 40-kDa form, which does not play a role in the increases in PKC␦ activity presented in our studies.
In conclusion, these results demonstrate that Srcrelated protein kinases and tyrosine phosphorylation participate in cellular events initiated by secretagogues acting on freshly isolated salivary acinar cells. DAG production, Src tyrosine kinases, and tyrosine phosphatases play integrated roles in the regulation of PKC␦ activity. In both salivary gland epithelial cells and PC-12 cells, two cell types that contain neither overexpressed PKC␦ nor overexpressed Src family members, the tyrosine phosphorylation of PKC␦ produced a positive effect on PKC␦ activity. This property of PKC␦ is important in our understanding of the biological function of PKC␦ in these and other cells.
